Veracyte Inc (FRA:12V)
€ 39.4 0.8 (2.07%) Market Cap: 3.16 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 2.76 GF Score: 81/100

Veracyte Inc at Wells Fargo Healthcare Conference Transcript

Sep 05, 2019 / 01:10PM GMT
Release Date Price: €23.18 (+1.05%)
Thomas Carbeau;Wells Fargo Securities;Co;Head of Equity Advisory
LLC

Good morning, everybody. Tom Carbeau, co-head of Equity Advisory here at Wells Fargo. Thanks for being here for our second day. We had almost 700 people here total yesterday and another good day. So appreciate everybody making their way to Boston.

Very excited to introduce Veracyte today, a leading genomic diagnostic company from South San Francisco with tests in thyroid, lung cancer, and IPF. The company's products are helping patients avoid unnecessary surgery. Very excited to have CEO, Bonnie Anderson here. She cofounded the company back in 2008. I think 18 years at Beckman Coulter prior. We also have the CFO and COO, Keith Kennedy, here as well. So I'll turn it over to Bonnie to run through the presentation by all means. We'll do some Q&A after.

Bonnie H. Anderson
Veracyte, Inc. - Co-Founder, Chairman & CEO

Sounds great. Thank you so much. Really appreciate the opportunity to be invited to your health care conference

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot